Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea
Karyopharm Therapeutics(KPTI) Prnewswire·2024-06-26 16:42- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treatment of adult patients with relapsed/refractory multiple myeloma (R/R MM). - The approval of XPOVIO® by the NHIS in South Korea is the fourth national reimbursement in the Antengene markets after mainland of China, Australia and Singapore. - Additional reimbursements of XPOVIO® in APAC markets are expected. - Antengene has also submitted the new drug applications (NDAs) in ...